Androgen Receptor Expression in Estrogen Receptor-Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations

Vessey MP. Effect of endogenous and exogenous hormones on breast cancer: epidemiology. Verh Dtsch Ges Pathol. 1997;81:493-501.

Xie B, Tsao SW, Wong YC. Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgens. Carcinogenesis. 1999;20:1597-1606.

Brys M, Wojcik M, Romanowicz-Makowska H, et al. Androgen receptor status in female breast cancer: RT-PCR and Western blot studies. J Cancer Res Clin Oncol. 2002;128:85-90.

Bryan RM, Mercer RJ, Bennett RC, et al. Androgen receptors in breast cancer. Cancer. 1984;54:2436-2440.

Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996;32A:1560-1565.

Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer: study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130:270-277.

Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer. 1984;53:630-643.

Osborne CK, Yochmowitz MG, Knight WA, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46:2884-2888.

Knight WA, Livingston RB, Gregory EJ, et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977;37:4669-4671.

Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292-1299.

Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol. 2001;106:111-125.

Park JJ, Irvine RA, Buchanan G, et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 2000;60:5946-5949.

Greene FL, Page DL, Fritz A, et al, eds. The AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002:223.

Brown RW, Allred CD, Clark GM, et al. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996;2:585-592.

Barnes DM, Dublin EA, Fisher CJ, et al. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993;24:469-476.

Secreto G, Toniolo P, Berrino F, et al. Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res. 1984;44:5902-5905.

Boccuzzi G, Tamagno E, Brignardello E, et al. Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide. J Cancer Res Clin Oncol. 1995;121:150-154.

Soreide JA, Lea OA, Varhaug JE, et al. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992;18:112-118.

Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993;170:31-35.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.